← All organizations
Highest phase reached
Phase 3
First clinical trial
Apr 1, 1993Last known activity
Mar 1, 2026
Timeline
1980s
- Jun 1, 1988
Federation Francophone de Cancerologie Digestive— Founded
Drugs by trial phase (43 distinct, 70 trials)
Phase 3 (23 own, 0 via acquisition)
Phase 2 (20 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenoma, Islet Cell
- Anus Neoplasms
- Bile Duct Neoplasms
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Hepatocellular
- Carcinoma, Neuroendocrine
- Carcinoma, Squamous Cell
- Cholangiocarcinoma
- Colonic Neoplasms
- Colorectal Neoplasms
- Endocrine Gland Neoplasms
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Gallbladder Neoplasms
- Gastrointestinal Neoplasms
- Liver Neoplasms
- Malignant Carcinoid Syndrome
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Second Primary
- Neuroendocrine Tumors
- Neutropenia
- Pancreatic Neoplasms
- Rectal Neoplasms
- Stomach Neoplasms
Recent trials (50)
- NCT07124858Lead sponsorN/AMar 1, 2026
- NCT07270991Lead sponsorPhase 3Dec 31, 2025
- NCT07150403Lead sponsorPhase 2Dec 31, 2025
- NCT07205731CollaboratorPhase 2Oct 31, 2025
- NCT07128290Lead sponsorPhase 2Oct 30, 2025
- NCT07124884Lead sponsorPhase 2Aug 31, 2025
- NCT05706779Lead sponsorPhase 2Feb 13, 2023
- NCT05665348Lead sponsorPhase 2/Phase 3Feb 1, 2023
- NCT05254639CollaboratorPhase 2Jun 2, 2022
- NCT04659382Lead sponsorPhase 2Oct 7, 2020
- NCT04325425Lead sponsorPhase 2Sep 1, 2020
- NCT04262687Lead sponsorPhase 2Apr 30, 2020
- NCT03959293Lead sponsorPhase 2Jul 15, 2019
- NCT03719924Lead sponsorPhase 2Mar 7, 2019
- NCT03760822Lead sponsorPhase 2Nov 16, 2018
Details
- Founded
- Paris, FR Jun 1, 1988
- Last known activity
- Mar 1, 2026